In the past week, GTHX stock has gone up by 3.51%, with a monthly decline of -10.22% and a quarterly surge of 4.56%. The volatility ratio for the week is 8.93%, and the volatility levels for the last 30 days are 7.76% for G1 Therapeutics Inc The simple moving average for the past 20 days is -4.13% for GTHX’s stock, with a 56.96% simple moving average for the past 200 days.
Is It Worth Investing in G1 Therapeutics Inc (NASDAQ: GTHX) Right Now?
Additionally, the 36-month beta value for GTHX is 1.71. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GTHX is 42.47M and currently, short sellers hold a 5.70% ratio of that float. The average trading volume of GTHX on May 02, 2024 was 1.20M shares.
GTHX) stock’s latest price update
G1 Therapeutics Inc (NASDAQ: GTHX)’s stock price has gone rise by 9.55 in comparison to its previous close of 3.77, however, the company has experienced a 3.51% increase in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-01 that G1 Therapeutics (GTHX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.53 per share a year ago.
Analysts’ Opinion of GTHX
Many brokerage firms have already submitted their reports for GTHX stocks, with JP Morgan repeating the rating for GTHX by listing it as a “Neutral.” The predicted price for GTHX in the upcoming period, according to JP Morgan is $10 based on the research report published on January 30, 2023 of the previous year 2023.
Needham, on the other hand, stated in their research note that they expect to see GTHX reach a price target of $31, previously predicting the price at $32. The rating they have provided for GTHX stocks is “Buy” according to the report published on January 03rd, 2023.
JP Morgan gave a rating of “Underweight” to GTHX, setting the target price at $19 in the report published on November 04th of the previous year.
GTHX Trading at 9.56% from the 50-Day Moving Average
After a stumble in the market that brought GTHX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.40% of loss for the given period.
Volatility was left at 7.76%, however, over the last 30 days, the volatility rate increased by 8.93%, as shares sank -12.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +82.74% upper at present.
During the last 5 trading sessions, GTHX rose by +3.51%, which changed the moving average for the period of 200-days by +69.26% in comparison to the 20-day moving average, which settled at $4.28. In addition, G1 Therapeutics Inc saw 35.41% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GTHX starting from Umstead John W. V, who sale 6,547 shares at the price of $3.02 back on Mar 18 ’24. After this action, Umstead John W. V now owns 123,896 shares of G1 Therapeutics Inc, valued at $19,752 using the latest closing price.
Malik Rajesh, the Chief Medical Officer of G1 Therapeutics Inc, sale 28,600 shares at $4.62 during a trade that took place back on Feb 12 ’24, which means that Malik Rajesh is holding 169,938 shares at $132,143 based on the most recent closing price.
Stock Fundamentals for GTHX
Current profitability levels for the company are sitting at:
- -0.48 for the present operating margin
- 0.91 for the gross margin
The net margin for G1 Therapeutics Inc stands at -0.64. The total capital return value is set at -0.43. Equity return is now at value -92.13, with -31.00 for asset returns.
Based on G1 Therapeutics Inc (GTHX), the company’s capital structure generated 0.6 points at debt to capital in total, while cash flow to debt ratio is standing at -0.73. The debt to equity ratio resting at 1.49. The interest coverage ratio of the stock is -6.81.
Currently, EBITDA for the company is -39.01 million with net debt to EBITDA at -0.68. When we switch over and look at the enterprise to sales, we see a ratio of 2.92. The receivables turnover for the company is 6.5for trailing twelve months and the total asset turnover is 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.87.
Conclusion
In conclusion, G1 Therapeutics Inc (GTHX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
